Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s ...

Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...

The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...

Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...

J&J said its latest TV ad, which highlights the psoriasis experience among people of color, is part of its broader effort to ...

(RTTNews) - Johnson & Johnson (JNJ) Monday announced positive results from Phase 3 GRAVITI study of Tremfya as both induction and maintenance therapy in Crohn's disease, a type of inflammatory bowel ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using this medication and each time you get a refill. Ask your health care professional how to ...